Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
- PMID: 21170740
- DOI: 10.1007/s12026-010-8187-5
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
Abstract
Recent research on hematological malignancies has shown that malignant cells often co-opt physiological pathways to promote their growth and development. Bone marrow homeostasis requires a fine balance between cellular differentiation and self-renewal; cell survival and apoptosis; and cellular proliferation and senescence. The Ras/Raf/MEK/ERK pathway has been shown to be important in regulating these biological functions. Moreover, the Ras/Raf/MEK/ERK pathway has been estimated to be mutated in 30% of all cancers, thus making it the focus of many scientific studies which have lead to a deeper understanding of cancer development and help to elucidate potential weaknesses that can be targeted by pharmacological agents [1]. In this review, we specifically focus on the role of this pathway in physiological hematopoiesis and how augmentation of the pathway may lead to hematopoietic malignancies. We also discuss the challenges and success of targeting this pathway.
Similar articles
-
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.Mol Cell Biol. 2003 Jan;23(2):543-54. doi: 10.1128/MCB.23.2.543-554.2003. Mol Cell Biol. 2003. PMID: 12509453 Free PMC article.
-
HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.J Cell Biochem. 2018 Mar;119(3):2864-2874. doi: 10.1002/jcb.26461. Epub 2017 Dec 12. J Cell Biochem. 2018. Retraction in: J Cell Biochem. 2021 Nov;122 Suppl 1:S14. doi: 10.1002/jcb.29973 PMID: 29073728 Retracted.
-
Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway.Mol Cell Biol. 2001 May;21(9):3192-205. doi: 10.1128/MCB.21.9.3192-3205.2001. Mol Cell Biol. 2001. PMID: 11287623 Free PMC article.
-
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12. Eur J Med Chem. 2016. PMID: 26807863 Review.
-
Ras/Raf signalling and emerging pharmacotherapeutic targets.Expert Opin Pharmacother. 2002 Jun;3(6):709-18. doi: 10.1517/14656566.3.6.709. Expert Opin Pharmacother. 2002. PMID: 12036410 Review.
Cited by
-
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.J Clin Invest. 2019 Mar 4;129(4):1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4. J Clin Invest. 2019. PMID: 30730307 Free PMC article.
-
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.Haematologica. 2019 Sep;104(9):1804-1811. doi: 10.3324/haematol.2017.185975. Epub 2019 Jan 17. Haematologica. 2019. PMID: 30655370 Free PMC article.
-
Natural Product Ginsenoside 20(S)-25-Methoxyl-Dammarane-3β, 12β, 20-Triol in Cancer Treatment: A Review of the Pharmacological Mechanisms and Pharmacokinetics.Front Pharmacol. 2020 Apr 22;11:521. doi: 10.3389/fphar.2020.00521. eCollection 2020. Front Pharmacol. 2020. PMID: 32425780 Free PMC article. Review.
-
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.Nat Commun. 2015 Jan 14;6:6042. doi: 10.1038/ncomms7042. Nat Commun. 2015. PMID: 25586593 Free PMC article.
-
Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Leukemia. 2017 Apr;31(4):922-933. doi: 10.1038/leu.2016.264. Epub 2016 Sep 30. Leukemia. 2017. PMID: 27686868
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous